X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/26/2870392/0/en/Apellis-Announces-Pegcetacoplan-MAA-Review-Has-Been-Reset-to-Day-180-of-Initial-Assessment-by-European-Medicines-Agency-EMA.html
https://investors.apellis.com/news-releases/news-release-details/apellis-announces-negative-chmp-opinion-pegcetacoplan-ga
https://www.globenewswire.com//news-release/2023/12/11/2793727/0/en/EMPAVELI-pegcetacoplan-Provided-Long-Term-Control-of-PNH-in-New-Data-Presented-at-ASH-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/11/04/2773579/0/en/SYFOVRE-pegcetacoplan-injection-Continued-to-Demonstrate-Increasing-Treatment-Effects-Over-3-Years-in-Patients-with-Geographic-Atrophy-GA.html
https://www.globenewswire.com//news-release/2023/10/20/2763970/0/en/The-Lancet-Publishes-24-Month-Results-from-Phase-3-Studies-of-SYFOVRE-pegcetacoplan-injection-for-Geographic-Atrophy-GA.html
https://www.globenewswire.com//news-release/2023/10/17/2761370/0/en/Apellis-to-Present-Positive-Phase-2-NOBLE-Results-of-Pegcetacoplan-in-Post-Transplant-Recurrence-of-Primary-IC-MPGN-and-C3G-at-Kidney-Week.html
https://www.globenewswire.com//news-release/2023/09/25/2748530/0/en/Apellis-Receives-Permanent-J-Code-J2781-for-SYFOVRE-pegcetacoplan-injection-Effective-October-1-2023.html
https://www.globenewswire.com//news-release/2023/08/29/2733224/0/en/Apellis-Announces-Corporate-Restructuring-to-Drive-Growth-of-SYFOVRE-pegcetacoplan-injection-and-EMPAVELI-pegcetacoplan-Positioning-Company-for-Long-Term-Success.html
https://www.globenewswire.com//news-release/2023/08/22/2730020/0/en/Apellis-Provides-Updates-on-Injection-Kits-and-Rare-Safety-Events-with-SYFOVRE-pegcetacoplan-injection.html
https://www.fiercepharma.com/pharma/apellis-attempts-clear-air-around-syfovre-safety-eye-med-reels-673m
https://investors.apellis.com/news-releases/news-release-details/syfovrer-pegcetacoplan-injection-continued-demonstrate
https://investors.apellis.com/news-releases/news-release-details/apellis-provides-update-review-rare-safety-events-syfovrer
https://www.fiercepharma.com/pharma/experts-flag-eye-inflammation-reports-tied-apellis-geographic-atrophy-med-syfovre
https://www.fiercepharma.com/pharma/apellis-scraps-pegcetacoplan-development-als-after-phase-2-trial-flop
https://www.biopharmadive.com/news/apellis-syfovre-geographic-atrophy-launch-sales-iveric/649556/
https://www.globenewswire.com/news-release/2023/04/21/2651829/0/en/Apellis-Announces-Validation-of-Four-Marketing-Applications-for-Pegcetacoplan-for-Geographic-Atrophy.html
https://www.europeanpharmaceuticalreview.com/news/179738/fda-approves-first-treatment-for-geographic-atrophy/
https://www.fiercepharma.com/pharma/apellis-wins-fda-approval-first-geographic-atrophy-drug#:~:text=Syfovre%20costs%20%242%2C190%20per%20vial,of%20the%20year's%20most%20uncertain.
https://www.globenewswire.com/news-release/2022/12/16/2575364/0/en/Apellis-Submits-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-Pegcetacoplan-for-Geographic-Atrophy.html
https://www.pharmaceutical-technology.com/news/health-canada-sobi-pnh-therapy/
https://www.globenewswire.com/news-release/2022/12/09/2571193/0/en/Sobi-Receives-Approval-from-Health-Canada-for-Empaveli-pegcetacoplan-for-the-Treatment-of-Certain-Patients-with-Paroxysmal-Nocturnal-Hemoglobinuria.html
https://www.fiercepharma.com/pharma/apellis-closely-watched-eye-drugs-gets-new-fda-goal-date-after-change-data-submission-scared
https://investors.apellis.com/news-releases/news-release-details/apellis-announces-plans-submit-24-month-phase-3-data-fda
https://investors.apellis.com/news-releases/news-release-details/apellis-present-new-long-term-data-reinforcing-robust-efficacy
https://www.globenewswire.com/news-release/2022/09/30/2526358/0/en/Apellis-Announces-24-Month-Phase-3-Post-Hoc-Results-Showing-Treatment-with-Pegcetacoplan-Led-to-Preservation-of-Function-in-High-Risk-Areas-of-the-Retina-in-Patients-with-Geographi.html
https://endpts.com/eye-focused-iveric-bio-reports-positive-phiii-readout-as-shares-surge-fda-filing-planned/
https://www.globenewswire.com/news-release/2022/08/24/2503714/0/en/Apellis-Announces-24-Month-Results-Showing-Increased-Effects-Over-Time-with-Pegcetacoplan-in-Phase-3-DERBY-and-OAKS-Studies-in-Geographic-Atrophy-GA.html
https://www.newswire.ca/news-releases/dri-healthcare-trust-announces-acquisition-of-a-royalty-interest-in-the-worldwide-sales-of-pegcetacoplan-including-empaveli-r-aspaveli-r-for-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria-898278513.html
https://www.globenewswire.com/news-release/2022/07/19/2481626/0/en/Avadel-Pharmaceuticals-Announces-Tentative-Approval-of-LUMRYZ-sodium-oxybate-extended-release-oral-suspension.html
https://www.globenewswire.com/news-release/2022/06/01/2454084/0/en/Apellis-Announces-Submission-of-New-Drug-Application-to-the-FDA-for-Pegcetacoplan-for-Geographic-Atrophy.html
https://www.globenewswire.com/news-release/2021/12/13/2351028/0/en/Apellis-and-Sobi-Report-Empaveli-pegcetacoplan-Demonstrated-Sustained-Normalization-of-Clinical-Measures-in-a-Broad-PNH-Patient-Population.html
https://www.thepharmaletter.com/article/nice-recommends-aspaveli-ahead-of-mhra-decision
https://www.fiercepharma.com/pharma/apellis-eye-med-application-track-after-fda-oks-inclusion-phase-2-data
https://www.globenewswire.com/news-release/2021/11/04/2327681/0/en/Apellis-to-Present-New-Data-Reinforcing-EMPAVELI-pegcetacoplan-Efficacy-and-Safety-in-Patients-with-PNH-at-the-2021-ASH-Annual-Meeting.html
https://www.fiercepharma.com/pharma/giddy-up-apellis-empaveli-could-reap-4b-annual-sales-its-race-against-alexion-s-soliris
https://www.prnewswire.com/news-releases/european-hematology-association---pegcetacoplan-maintains-a-durable-response-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-through-week-48-301308054.html
https://www.prnewswire.com/news-releases/european-hematology-association---pegcetacoplan-maintains-a-durable-response-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-through-week-48-301308054.html
https://endpts.com/apellis-soliris-rival-gets-a-date-at-the-fda-for-a-rare-blood-disorder-with-potentially-400m-worth-of-implications/
https://www.globenewswire.com/news-release/2020/07/02/2056888/0/en/Apellis-Completes-Enrollment-in-Phase-3-Study-of-Pegcetacoplan-in-Treatment-Na%C3%AFve-Patients-with-Paroxysmal-Nocturnal-Hemoglobinuria-PNH.html
https://endpts.com/apellis-says-its-ready-to-file-for-an-ok-on-their-soliris-rival-after-regulators-clear-a-roadblock/
Market Place
Share 
